BLA Filings
The application to approve a biologic — antibodies, vaccines, cell and gene therapies — that opens the FDA review toward a PDUFA date.
December 20261
About BLA Filings
A Biologics License Application (BLA) is the submission a company files to market a biologic product — monoclonal antibodies, vaccines, blood products, and cell or gene therapies — in the United States. It is the biologics equivalent of an NDA.
Like an NDA, a BLA is subject to an FDA acceptance decision that establishes the PDUFA goal date, and it can receive Priority Review. Given the rise of antibody, cell and gene-therapy pipelines, BLAs now account for many of the highest-value approvals.
Why BLA Filings matter to investors
BLA filings mark the transition of a biologic from development to a potential product launch. Because biologics command premium pricing and long exclusivity, a BLA acceptance — especially with Priority Review or a rolling submission — is a meaningful de-risking event for the sponsor.
Frequently asked questions
What is a BLA filing?
A Biologics License Application is the formal request to the FDA to approve a biologic — such as an antibody, vaccine, or cell/gene therapy. It starts the review clock toward a PDUFA date.
How is a BLA different from an NDA?
A BLA covers biologics (large, biologically produced molecules); an NDA covers small-molecule drugs. Both use the FDA’s PDUFA review timeline and can earn Priority Review.
What is a rolling BLA submission?
A rolling submission lets a sponsor file portions of the application as they are completed — often granted with Breakthrough Therapy designation — which can accelerate the path to a decision.